Feb. 13 at 2:27 PM
$MODD The Company confidently disclosed that it's on schedule for Q1 launch. FDA news will likely follow shortly but this is a keeper for longterm considering the fact that it is the only tubeless insulin pump other than Insulet (PODD) that trades average
$250 . The other tube pump competetors TNDM and MDT are at
$20 and
$100. MODD could reach at least
$10 by year end IMO. Numerous catalysts are expected including EU market aproval.